Aldeyra Therapeutics (ALDX) Current Deferred Revenue (2023 - 2025)

Aldeyra Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $6.0 million for Q4 2025.

• Quarterly Current Deferred Revenue changed 0.0% year-over-year to $6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $6.0 million, changed 0.0% from the prior year.
• Current Deferred Revenue was $6.0 million for Q4 2025 at Aldeyra Therapeutics, roughly flat from $6.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $6.0 million in Q4 2023 and bottomed at $6.0 million in Q4 2023.
• A 3-year average of $6.0 million and a median of $6.0 million in 2023 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
• Aldeyra Therapeutics' Current Deferred Revenue stood at $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024, then changed by 0.0% to $6.0 million in 2025.
• Business Quant data shows ALDX's Current Deferred Revenue at $6.0 million in Q4 2025, $6.0 million in Q4 2024, and $6.0 million in Q3 2024.